Overview

Adnexus, a Bristol-Myers Squibb R&D Company, is leading the discovery and development of Adnectins™, a novel, proprietary class of targeted biologics. Adnectins are proteins designed to either block or stimulate therapeutic targets of interest to fight diseases across a broad range of therapeutic areas. Our proprietary technology for engineering these versatile proteins creates an opportunity to rapidly generate highly differentiated medicines.

Targeted biologics are one of the most medically important and fastest growing areas in the biopharmaceutical industry. These drugs are specifically designed to attack targets of disease. Despite the success of the first generation targeted therapeutic products, such as antibodies, additional innovations are sought by the medical community in terms of improved safety, efficacy and convenience. We believe Adnectins will become a new, significant class of targeted biologics that address these demands and offer important advantages over traditional antibody and small molecule therapeutics.

Adnectins are derived from human fibronectin, an abundant extracellular protein that binds naturally to a number of different proteins. We create Adnectins using our proprietary protein engineering system called PROfusion.™ Our scientists can rapidly create PROfusion libraries of more than 10 trillion different Adnectins. We then screen these libraries to identify Adnectins with the desired drug properties against therapeutic targets of interest. PROfusion enables a revolutionary improvement in discovery productivity by minimizing the timeframe for identifying high-quality candidates.

In October 2007, Adnexus was acquired by Bristol-Myers Squibb Company (BMS). This acquisition has further accelerated our growth as an industry leader in the advancement of novel-targeted biologics. With the experience and support of BMS, we are continuing the clinical development of our lead Adnectin candidate, CT-322, and advancing multiple other Adnectin therapies for the treatment of a broad range of disease types, including oncology, immunology, and cardiovascular disease.

Our Vision

We believe Adnectins will become a new, significant class of targeted biologics that addresses important industry demands for improved safety, efficacy, and convenience.